BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21400515)

  • 1. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
    Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
    Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
    Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
    Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
    Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
    Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
    Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
    Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
    Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
    Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
    Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
    Chu S; Li L; Singh H; Bhatia R
    Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
    Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
    Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
    Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
    Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.